Skip to content
FY'25FY'24FY'23FY'22
Total net sales from international sources by Business
Analytical Reference Standards and Services segment$900K0.0%$900K-10.0%$1M-23.1%$1.3M+18.2%
Consumer Products segment$20.2M+2.0%$19.8M-7.0%$21.3M+15.8%$18.4M+2.2%
Ingredients segment$6.7M+86.1%$3.6M+33.3%$2.7M+28.6%$2.1M+200%
Gain On Settlement Of Royalty Obligation by Business
Analytical Reference Standards and Services segment$0
Consumer Products segment$1.62M
Ingredients segment$368K
Pharmaceuticals segment$0
Selling by Business
Analytical Reference Standards and Services segment$347K-30.2%$497K+37.3%$362K
Consumer Products segment$10.77M+15.9%$9.29M+10.5%$8.4M
Ingredients segment$144K+260%$40K-23.1%$52K
Marketing by Business
Analytical Reference Standards and Services segment$2K-50.0%$4K-60.0%$10K
Consumer Products segment$11.49M+37.7%$8.35M+13.5%$7.35M
Ingredients segment$102K-47.7%$195K$0
Advertising by Business
Analytical Reference Standards and Services segment$0$0$0
Consumer Products segment$12.66M+14.0%$11.1M+8.2%$10.26M
Ingredients segment$0$0$0

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Niagen Bioscience, Inc. Common Stock break its business down?
Niagen Bioscience, Inc. Common Stock (NAGE) reports net sales by business across 5 parts — Analytical Reference Standards and Services segment, Consumer Products segment, Corporate and other, Ingredients segment and Pharmaceuticals segment. Each is extracted from the segment footnotes and tracked over time.
Where does Niagen Bioscience, Inc. Common Stock's segment data come from?
Segment breakdowns are pulled from the segment footnotes in Niagen Bioscience, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.